CompletedPhase 2NCT00002494
Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia
Studying Burkitt lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Alliance for Clinical Trials in Oncology
- Principal Investigator
- Edward Lee, MD, MDCentral Maryland Oncology Center
- Intervention
- cyclophosphamide(drug)
- Enrollment
- 134 enrolled
- Eligibility
- 15 years · All sexes
- Timeline
- 1992 – 2006
Study locations (23)
- University of California San Diego Cancer Center, La Jolla, California, United States
- UCSF Cancer Center and Cancer Research Institute, San Francisco, California, United States
- CCOP - Christiana Care Health Services, Wilmington, Delaware, United States
- Walter Reed Army Medical Center, Washington D.C., District of Columbia, United States
- CCOP - Mount Sinai Medical Center, Miami Beach, Florida, United States
- University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
- Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States
- Sinai Hospital of Baltimore, Baltimore, Maryland, United States
- University of Massachusetts Memorial Medical Center, Worcester, Massachusetts, United States
- University of Minnesota Cancer Center, Minneapolis, Minnesota, United States
- Ellis Fischel Cancer Center - Columbia, Columbia, Missouri, United States
- Barnes-Jewish Hospital, St Louis, Missouri, United States
- CCOP - Southern Nevada Cancer Research Foundation, Las Vegas, Nevada, United States
- Norris Cotton Cancer Center, Lebanon, New Hampshire, United States
- Roswell Park Cancer Institute, Buffalo, New York, United States
- +8 more locations on ClinicalTrials.gov
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00002494 on ClinicalTrials.govOther trials for Burkitt lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07069699Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC GeneNational Cancer Institute (NCI)
- RECRUITINGEARLY PHASE1NCT07429461Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic LeukemiaZhejiang University
- RECRUITINGEARLY PHASE1NCT06793241Donor Derived CD19 CAR-T Cells in the Treatment of R/R B-cell Acute Lymphoblastic LeukemiaZhejiang University
- RECRUITINGPHASE2, PHASE3NCT06764238Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL ProtocolInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGNCT06796517Immunotherapy in LymphomaSung-Soo Park
- RECRUITINGPHASE1NCT06060782Thiotepa, Cyclophosphamide, Clarithromycin and CytarabineFifth Affiliated Hospital, Sun Yat-Sen University
- RECRUITINGPHASE2NCT06179524CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALLBeijing Yongtai Ruike Biotechnology Company Ltd
- RECRUITINGPHASE1NCT06056752QH103 Cell Injection for the Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic LeukemiaAnhui Provincial Hospital